+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2017-08-08Number of Pages: 153

Alpha 1 Antitrypsin Deficiency Treatment Market (Treatment Type - Augmentation Therapy, Bronchodilators, Corticosteroids, and Oxygen Therapy; End-user - Hospitals, Specialty Clinics, and Pharmacies; Route of Administration - Parenteral, Inhalation, and Oral) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Global Alpha-1 Antitrypsin Deficiency Treatment Market: Snapshot

The demand in the global alpha-1 antitrypsin deficiency treatment market is projected to increment at an admirable CAGR of 10.3% during the forecast period of 2017 to 2025, gaining traction from a number of factors such as improvements in the diagnostics of alpha-1 antitrypsin deficiency, improving economic scenario in various emerging economies, ample of opportunities in the development of new products, and high unmet demand across the globe. On the other hand, stringent regulations, high cost of drugs, and limited plasma fractionation capacity are some of the hindrances faced by the market, and until these are overcome, the prosper prosperity will not be achieved.

The global alpha-1 antitrypsin deficiency treatment market is estimated to reach a valuation of US$2,908.1 mn by the end of 2025, notably up from its evaluated worth of US$1,224.5 mn in 2016. The stockholders of the global alpha-1 antitrypsin deficiency treatment market are expected to gain new opportunities in the near future via strategic alliances and growing awareness regarding this deficiency disease.

alpha-1-antitrypsin-deficiency-treatment-market

Augmentation Therapy Profitable Treatment Segment

On the basis of treatment type, the global alpha-1 antitrypsin deficiency treatment market is segmented into augmentation therapy, bronchodilator, corticosteroids, and oxygen therapy. The segment of augmentation therapy, which is further sub-segmented into aralast, prolastin, glassia, and zemaira or respreeza, currently serves the maximum demand in the global alpha-1 antitrypsin deficiency treatment market, and is expected to sustain its position by the end of 2025, followed by bronchodilator treatment segment. Based on end-user, the AATD market gains maximum demand from hospitals, although specialty clinics are projected for most prominent growth rate. This report also segments the alpha-1 antitrypsin deficiency treatment market on the basis of route of administration, into inhalations, parenteral, and oral, and rates parenteral segment as the most profitable route of administration, which is a reflection of benefits such as ease of drug administration and high chances of avoiding first-pass metabolism.

North America and Europe Most Lucrative Regions

Out of the five regions that this report breaks the market for alpha-1 antitrypsin deficiency treatment into, viz. North America, Asia Pacific, Europe, The Middle East and Africa, and Latin America, North America served the maximum demand in 2016, although the share of the demand is likely to slightly decrease towards the end of the forecast period. High prevalence of alpha-1 antitrypsin deficiency among the population of developed countries of the U.S. and Canada, escalting diagnosis rates, high plasma yield, and high per capita health care expenditure are some of the key factors resulting the strong demand from North America. On the other hand, Europe, which is second most lucrative region for the vendors operating in the global alpha-1 antitrypsin deficiency market, is projected for the best CAGR among all the regions, showcasing the increasing awareness regarding alpha-1 antitrypsin deficiency and high prevalence.

Some of the key companies currently competing in the global alpha-1 antitrypsin  treatment market are Pfizer Inc., Baxter, AstraZeneca, Grifols S.A., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Kamada Ltd., GlaxoSmithKline Plc., CSL Behring LLC, Shire plc, LFB Biomedicaments S.A., Abeona Therapeutics, Biogen, Applied Genetic Technologies Corp, Baxalta, Arrowhead Research Corporation, ProBioGen, Chiesi Pharmaceuticals, Curaxys, and ProMetic Life Sciences. The landscape of the competition in the global AATD market is largely fragmented, marked by frequent mergers and acquisitions by the leading vendors to maintain their position.

Chapter 1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights

Chapter 2. Assumptions and Research Methodology
2.1. Assumptions
2.2. Research Methodology

Chapter 3. Executive Summary: 
3.1. Global Alpha-1 Antitrypsin Deficiency Treatment: Market Snapshot         
3.2. Market Share Analysis by Region, 2016

Chapter 4. Market Overview
4.1. Market Overview
4.2. Global Alpha-1 Antitrypsin Deficiency Treatment Market : Market Indicators
4.3. Global Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, 2015–2025
4.4. Global Alpha-1 Antitrypsin Deficiency Treatment Market : Market Outlook

Chapter 5. Market Dynamics
5.1. Drivers and Restraints Snapshot Analysis
5.2. Drivers
       5.2.1. Increase in prevalence and incidence of respiratory diseases
       5.2.2. Improved technology for production and purification methods
       5.2.3. Rise in prescription of combination therapies
       5.2.4. High R&D in asthma and COPD treatment
       5.2.5. Increasing awareness programs
       5.2.6. Favorable government initiatives and approvals
       5.2.7. Rise in health care spending and improvement health care infrastructure
       5.2.8. Development of better diagnostic methods
5.3. Restraints
       5.3.1. High cost of treatment
       5.3.2. Chronic side effects
       5.3.3. Demand-supply gap
       5.3.4. Limitation regarding reliable clinical data
       5.3.5. Low diagnosis rate
5.4. Opportunities
       5.4.1. Alternative potential therapies
       5.4.2. Increasing global plasma yield to offer significant opportunities to new entrants
5.5. Key Trends
5.6. Alpha-1 Antitrypsin Deficiency Treatment Market: Value Chain Analysis
5.7. Comparative Brand Analysis
5.8. Porter’s Five Forces Analysis 
5.9. Epidemiology: Alpha-1 Antitrypsin Deficiency
5.10. Pipeline Analysis: Alpha-1 Antitrypsin Deficiency Treatment Market
5.11. Clinical Trials: Alpha-1 Antitrypsin Deficiency Treatment Market

Chapter 6. Alpha-1 Antitrypsin Deficiency Treatment Market Analysis, by Treatment
6.1. Introduction 
6.2. Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Treatment
6.3. Alpha-1 Antitrypsin Deficiency Treatment Market Forecast, by Treatment
       6.3.1. Augmentation Therapy
                 6.3.1.1. Aralast
                 6.3.1.2. Prolastin
                 6.3.1.3. Zemaira/Respreeza
                 6.3.1.4. Glassia
       6.3.2. Bronchodilator
       6.3.3. Corticosteroids
       6.3.4. Oxygen Therapy
       6.3.5. Others
6.4. Market Attractiveness Analysis, by Treatment

Chapter 7. Alpha-1 Antitrypsin Deficiency Treatment Market Analysis, by End-user
7.1. Introduction 
7.2. Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by End-User
7.3. Alpha-1 Antitrypsin Deficiency Treatment Market Forecast, by End-user
       7.3.1. Specialty Clinics
       7.3.2. Hospitals
       7.3.3. Pharmacies 
7.4. Market Attractiveness, by End-User

Chapter 8. Alpha-1 Antitrypsin Deficiency Treatment Market Analysis, by Route of Administration
8.1. Introduction 
8.2. Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Route of Administration
       8.2.1. Alpha-1 Antitrypsin Deficiency Treatment Market Forecast, by Route of Administration 
       8.2.2. Parenteral
       8.2.3. Inhalation
       8.2.4. Oral
8.3. Market Attractiveness by Route of Administration

Chapter 9. Alpha-1 Antitrypsin Deficiency Treatment Market Analysis, by Region
9.1. Global Alpha-1 Antitrypsin Deficiency Treatment Market, Regional Outlook
9.2. Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Region
9.3. Alpha-1 Antitrypsin Deficiency Treatment Market Forecast, by Region
9.4. Market Attractiveness Analysis, by Region

Chapter 10. North America Alpha-1 Antitrypsin Deficiency Treatment Market Analysis
10.1. Market Overview
10.2. Market Analysis, by Treatment
       10.2.1. Market Value Share Analysis, by Treatment
       10.2.2. Market Size (US$ Mn) Forecast, by Treatment
                 10.2.2.1. Augmentation Therapy
                             10.2.2.1.1. Aralast
                             10.2.2.1.2. Prolastin
                             10.2.2.1.3. Zemaira/Respreeza
                             10.2.2.1.4. Glassia
                 10.2.2.2. Bronchodilator
                 10.2.2.3. Corticosteroids
                 10.2.2.4. Oxygen Therapy
                 10.2.2.5. Others
10.3. Market size (US$ Mn), by End-user
       10.3.1. Market Value Share Analysis, by End-user
       10.3.2. Market Size (US$ Mn) Forecast, by End-user
                 10.3.2.1. Specialty Clinics
                 10.3.2.2. Hospitals
                 10.3.2.3. Pharmacies
10.4. Market size (US$ Mn) Forecast, by Country
       10.4.1. Market Value Share Analysis, by Country
       10.4.2. Market Size (US$ Mn) Forecast, by Country, 2017–2025
                 10.4.2.1. U.S.
                 10.4.2.2. Canada
10.5. Market Attractiveness Analysis 
       10.5.1. By Treatment
       10.5.2. By End-user
       10.5.3. By Country 

Chapter 11. Europe Alpha-1 Antitrypsin Deficiency Treatment Market Analysis
11.1. Market Overview
11.2. Market Analysis, by Treatment
       11.2.1. Market Value Share Analysis, by Treatment
       11.2.2. Market Size (US$ Mn) Forecast, by Treatment
                 11.2.2.1. Augmentation Therapy
                             11.2.2.1.1. Aralast
                             11.2.2.1.2. Prolastin
                             11.2.2.1.3. Zemaira/Respreeza
                             11.2.2.1.4. Glassia
                 11.2.2.2. Bronchodilator
                 11.2.2.3. Corticosteroids
                 11.2.2.4. Oxygen Therapy
                 11.2.2.5. Others
11.3. Market size (US$ Mn), by End-user
       11.3.1. Market Value Share Analysis, by End-user
                 11.3.2. Market Size (US$ Mn) Forecast, by End-user
                 11.3.2.1. Specialty Clinics
                 11.3.2.2. Hospitals
                 11.3.2.3. Pharmacies
11.4. Market size (US$ Mn) Forecast, by Country
       11.4.1. Market Value Share Analysis, by Country
       11.4.2. Market Size (US$ Mn) Forecast, by Country, 2017–2025
                 11.4.2.1. U.K.
                 11.4.2.2. Germany
                 11.4.2.3. France 
                 11.4.2.4. Italy
                 11.4.2.5. Spain
                 11.4.2.6. Rest of Europe
11.5. Market Attractiveness Analysis 
       11.5.1. By Treatment
       11.5.2. By End-user
       11.5.3. By Country

Chapter 12. Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Analysis
12.1. Market Overview
12.2. Market Analysis, by Treatment
       12.2.1. Market Value Share Analysis, by Treatment
       12.2.2. Market Size (US$ Mn) Forecast, by Treatment
                 12.2.2.1. Augmentation Therapy
                             12.2.2.1.1. Aralast
                             12.2.2.1.2. Prolastin
                             12.2.2.1.3. Zemaira/Respreeza
                             12.2.2.1.4. Glassia
                 12.2.2.2. Bronchodilator
                 12.2.2.3. Corticosteroids
                 12.2.2.4. Oxygen Therapy
                 12.2.2.5. Others
12.3. Market size (US$ Mn), by End-user
       12.3.1. Market Value Share Analysis, by End-user
       12.3.2. Market Size (US$ Mn) Forecast, by End-user
                 12.3.2.1. Specialty Clinics
                 12.3.2.2. Hospitals
                 12.3.2.3. Pharmacies
12.4. Market size (US$ Mn) Forecast, by Country
       12.4.1. Market Value Share Analysis, by Country
       12.4.2. Market Size (US$ Mn) Forecast, by Country, 2017–2025
                 12.4.2.1. Australia
                 12.4.2.2. Rest of Asia Pacific
12.5. Market Attractiveness Analysis 
       12.5.1. By Treatment
       12.5.2. By End-user
       12.5.3. By Country

Chapter 13. Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Analysis
13.1. Market Overview
13.2. Market Analysis, by Treatment
       13.2.1. Market Value Share Analysis, by Treatment
       13.2.2. Market Size (US$ Mn) Forecast, by Treatment
                 13.2.2.1. Augmentation Therapy
                             13.2.2.1.1. Aralast
                             13.2.2.1.2. Prolastin
                             13.2.2.1.3. Zemaira/Respreeza
                             13.2.2.1.4. Glassia
                 13.2.2.2. Bronchodilator
                 13.2.2.3. Corticosteroids
                 13.2.2.4. Oxygen Therapy
                 13.2.2.5. Others
13.3. Market size (US$ Mn), by End-user
       13.3.1. Market Value Share Analysis, by End-user
                 13.3.2. Market Size (US$ Mn) Forecast, by End-user
                 13.3.2.1. Specialty Clinics
                 13.3.2.2. Hospitals
                 13.3.2.3. Pharmacies
13.4. Market size (US$ Mn) Forecast, by Country
       13.4.1. Market Value Share Analysis, by Country
       13.4.2. Market Size (US$ Mn) Forecast, by Country, 2017–2025
                 13.4.2.1. Brazil
                 13.4.2.2. Mexico
                 13.4.2.3. Rest of LATAM
13.5. Market Attractiveness Analysis 
       13.5.1. By Treatment
       13.5.2. By End-user
       13.5.3. By Country

Chapter 14. Middle East and Africa Alpha-1 Antitrypsin Deficiency Treatment Market Analysis
14.1. Market Overview
14.2. Market Analysis, by Treatment
       14.2.1. Market Value Share Analysis, by Treatment
       14.2.2. Market Size (US$ Mn) Forecast, by Treatment
                 14.2.2.1. Augmentation Therapy
                             14.2.2.1.1. Aralast
                             14.2.2.1.2. Prolastin
                             14.2.2.1.3. Zemaira/Respreeza
                             14.2.2.1.4. Glassia
                 14.2.2.2. Bronchodilator
                 14.2.2.3. Corticosteroids
                 14.2.2.4. Oxygen Therapy
                 14.2.2.5. Others
14.3. Market size (US$ Mn), by End-user
       14.3.1. Market Value Share Analysis, by End-user
       14.3.2. Market Size (US$ Mn) Forecast, by End-user
                 14.3.2.1. Specialty Clinics
                 14.3.2.2. Hospitals
                 14.3.2.3. Pharmacies
14.4. Market size (US$ Mn) Forecast, by Country
       14.4.1. Market Value Share Analysis, by Country
       14.4.2. Market Size (US$ Mn) Forecast, by Country, 2017–2025
                 14.4.2.1. South Africa
                 14.4.2.2. Saudi Arabia
                 14.4.2.3. Rest of MEA
14.5. Market Attractiveness Analysis 
       14.5.1. By Treatment
       14.5.2. By End-user
       14.5.3. By Country

Chapter 15. Competition Landscape
15.1. Alpha-1 Antitrypsin Deficiency Treatment Market Share Analysis, by Company (2016)
15.2. Company Profiles
       15.2.1. Grifols, S.A.
                 15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                 15.2.1.2. Product Portfolio
                 15.2.1.3. SWOT Analysis
                 15.2.1.4. Strategic Overview
       15.2.2. AstraZeneca
                 15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                 15.2.2.2. Product Portfolio
                 15.2.2.3. SWOT Analysis
                 15.2.2.4. Strategic Overview
       15.2.3. Teva Pharmaceutical Industries Ltd.
                 15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                 15.2.3.2. Product Portfolio
                 15.2.3.3. SWOT Analysis
                 15.2.3.4. Strategic Overview
       15.2.4. Boehringer Ingelheim GmbH
                 15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                 15.2.4.2. Product Portfolio
                 15.2.4.3. SWOT Analysis
                 15.2.4.4. Strategic Overview
       15.2.5. GlaxoSmithKline Plc.
                 15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                 15.2.5.2. Product Portfolio
                 15.2.5.3. SWOT Analysis
                 15.2.5.4. Strategic Overview
       15.2.6. CSL Behring LLC
                 15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                 15.2.6.2. Product Portfolio
                 15.2.6.3. SWOT Analysis
                 15.2.6.4. Strategic Overview
       15.2.7. Shire plc
                 15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                 15.2.7.2. Product Portfolio
                 15.2.7.3. SWOT Analysis
                 15.2.7.4. Strategic Overview
       15.2.8. Pfizer Inc.
                 15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                 15.2.8.2. Product Portfolio
                 15.2.8.3. SWOT Analysis
                 15.2.8.4. Strategic Overview
       15.2.9. LFB Biomedicaments S.A.
                 15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                 15.2.9.2. Product Portfolio
                 15.2.9.3. SWOT Analysis
                 15.2.9.4. Strategic Overview
       15.2.10. Kamada Ltd
                 15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                 15.2.10.2. Product Portfolio
                 15.2.10.3. SWOT Analysis
                 15.2.10.4. Strategic Overview

List of Figures

Figure 01: Alpha-1 Antitrypsin Deficiency Treatment Market Snapshot
Figure 02: Global Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
Figure 03: Market Value Share By Treatment Type (2016)
Figure 04: Market Value Share By End-user (2016)
Figure 05: Market Value Share By Region(2016)
Figure 06: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Treatment, 2016 and 2025
Figure 07: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Augmentation Therapy, 2015–2025
Figure 08: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Bronchodilators, 2015–2025
Figure 09: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Corticosteroids, 2015–2025
Figure 10: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Oxygen Therapy, 2015–2025
Figure 11: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2015–2025
Figure 12: Global Aralast Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 13: Global Prolastin Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 14: Global Zemaira/Respreeza Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 15: Global Glassia Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 16: Global Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Treatment
Figure 17: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by End-user, 2016 and 2025
Figure 18: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Specialty Clinics, 2015–2025
Figure 19: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospitals, 2015–2025
Figure 20: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Pharmacies, 2015–2025
Figure 21: Global Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by End-user
Figure 22: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Route of Administration, 2016 and 2025
Figure 23: Global Parenteral Market Revenue, US$ Mn,
Figure 24: Global Inhalation Market Revenue, US$ Mn,
Figure 25: Global Oral Market Revenue, US$ Mn, 2015–2025
Figure 26: Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Route of Administration
Figure 27: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Region, 2016 and 2025
Figure 28: Global Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Region
Figure 29: North America Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, 2017–2025
Figure 30: North America Market Attractiveness Analysis, by Country
Figure 31: North America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Treatment, 2016 and 2025
Figure 32: North America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by End-user, 2016 and 2025
Figure 33: North America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Country, 2016 and 2025
Figure 34: North America Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Treatment
Figure 35: North America Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by End-user
Figure 36: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, 2017–2025
Figure 37: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Country
Figure 38: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Treatment, 2016 and 2025
Figure 39: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by End-user, 2016 and 2025
Figure 40: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Country, 2016 and 2025
Figure 41: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Treatment
Figure 42: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by End-user
Figure 43: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, 2015–2025
Figure 44: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Country
Figure 45: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Treatment, 2016 and 2025
Figure 46: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by End-user, 2016 and 2025
Figure 47: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Country, 2016 and 2025
Figure 48: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Treatment
Figure 49: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by End-user
Figure 50: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, 2015–2025
Figure 51: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Country
Figure 52: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Treatment, 2016 and 2025
Figure 53: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by End-user, 2016 and 2025
Figure 54: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Country, 2016 and 2025
Figure 55: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Treatment
Figure 56: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by End-user
Figure 57: Middle East & Africa Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, 2015–2025
Figure 58: Middle East & Africa Market Attractiveness Analysis, by Country
Figure 59: Middle East & Africa Market Value Share Analysis, by Treatment, 2016 and 2025
Figure 60: Middle East & Africa Market Value Share Analysis, by End-user, 2016 and 2025
Figure 61: Middle East & Africa Market Value Share Analysis, by Country, 2016 and 2025
Figure 62: Middle East & Africa Market Attractiveness Analysis, by Treatment
Figure 63: Middle East & Africa Market Attractiveness Analysis, by End-user
Figure 64: Global Alpha-1 Antitrypsin Deficiency Treatment Market Share Analysis, by Company (2016)
Figure 65: Grifols, S.A. Breakdown of Net Sales, by Region, 2016
Figure 66: Grifols, S.A. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 67: AstraZeneca Breakdown of Net Sales, by Region, 2016
Figure 68: AstraZeneca Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 69: Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, by Region, 2016
Figure 70: Teva Pharmaceutical Industries Ltd. Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 71: Boehringer Ingelheim GmbH Breakdown of Net Sales, by Region (2016)
Figure 72: Boehringer Ingelheim GmbH Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 73: GlaxoSmithKline Plc. Breakdown of Net Sales, by Region, 2016
Figure 74: GlaxoSmithKline Plc. Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 75: CSL Behring LLC Breakdown of Net Sales, by Region, 2016
Figure 76: CSL Behring LLC Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
Figure 77: Shire plc Breakdown of Net Sales, by Segment, 2016
Figure 78: Shire plc Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 79: Pfizer Inc. Breakdown of Net Sales, by Region, 2016
Figure 80: Pfizer Inc. Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 81: LFB Biomedicaments S.A. Breakdown of Net Sales, by Region, 2015
Figure 82: LFB Biomedicaments S.A. Revenue (US$ Mn) & Y-o-Y Growth (%), 2012–2015
Figure 83: Kamada Ltd. Breakdown of Net Sales (2016), by Segments
Figure 84: Kamada Ltd. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016

List of Tables

Table 01: Comparative Analysis of Approved Alpha-1 Antitrypsin Replacement Therapy Brands
Table 02: Pipeline Analysis: Alpha-1 Antitrypsin Deficiency Treatment Market
Table 03: Clinical Trials: Alpha-1 Antitrypsin Deficiency Treatment Market
Table 04: Global Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2025
Table 05: Global Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2025
Table 06: Global Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2025
Table 07: Global Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Region, 2017–2025
Table 08: North America Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2025
Table 09: North America Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2025
Table 10: North America Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Country, 2017–2025
Table 11: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2025
Table 12: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2025
Table 13: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Country, 2017–2025
Table 14: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2025
Table 15: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2025
Table 16: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Country, 2017–2025 
Table 16: Table 17: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Treatment, 2015–2025
Table 18: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by End-user, 2015–2025
Table 19: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 20: Middle East & Africa Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2015–2025
Table 21: Middle East & Africa Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by End-user, 2015–2025
Table 22: Middle East & Africa Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Country, 2015–2025

Global Alpha-1 Antitrypsin Deficiency Treatment Market: Overview

Alpha-1 Antitrypsin also referred as AAT, is a type of protein belongs to the class protease inhibitor. This protein is produced in the liver and is primarily functions to protect the lungs and liver from the harmful effects of other protein in the body. The AAT deficiency is genetic disorder that causes low and defective production of AAT proteins in liver which results in the accumulation of AAT in the liver and low amount of it in blood stream. The presence of AAT deficiency can be diagnosed using blood test, genetic tests and biopsy tests. Patients with severe AAT deficiency get affected by liver cirrhosis, chronic obstructive pulmonary diseases (COPD), and emphysema diseases. The diagnosis rate for alpha-1 antitrypsin deficiency across the globe is one of the crucial indicators of the alpha-1 antitrypsin deficiency treatment market. The AAT deficiency disease can be treated using different therapeutic methods such as augmentation therapy, bronchodilators, corticosteroids, oxygen therapy and other treatment methods.

Global Alpha-1 Antitrypsin Deficiency Treatment Market: Trends and Opportunities

The worldwide increase in the incidences and prevalence of respiratory diseases is projected to be key driving factor for the global AAT deficiency market during forecast period. According to the Forum of International Respiratory Societies (FIRS), COPD affects more than 200 million people and is likely to be the fourth leading cause of death in the world by 2030, while asthma affects about 235 million people globally. AAT deficiency is most commonly observed in the North America and European countries which is likely to drive the market. The increasing awareness about AAT deficiency disorder in developed countries, technological development in in the production and purification of Alpha-1 Antitrypsin protein, and government initiatives for increasing blood and plasma derived products would boost the growth of global AAT deficiency treatment market. The AAT deficiency is common, but under diagnosed condition in most of countries. The slow diagnosis rates of AAT deficiency and high cost of treatment is likely to hamper growth of global AAT deficiency treatment market over forecast period. Alpha-1 antitrypsin deficiency (A1AD) mostly occurs in the Caucasian population of European descent, affecting approximately 100,000 Americans. However, most cases of A1AD are undetected, making alpha-1 antitrypsin deficiency a highly under-diagnosed disorder. Also the treatment of AAT deficiency may lead to development of several chronic side effects such as back/joint pain, chest pain, musculoskeletal pain, rhinorrhea, sinusitis, fever, nausea, or shortness of breath, peripheral edema, and urticarial. These side effects can sometimes force a patient to discontinue the therapy as alpha-1 antitrypsin is a natural enzyme inhibitor product.

Global Alpha-1 Antitrypsin Deficiency Treatment Market: Geographical Segmentation

Geographically, the global AAT deficiency treatment market has been segmented into five regions: North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. The North America dominated the global AAT deficiency treatment market in 2016 and is likely to lose its market share to Europe by the end of 2025.  Europe is projected to expand at highest CAGR during forecast period and is likely to gain its market share by the end of 2025. All the regions have been further segmented by countries, product type, by material and End-user segments. The competition matrix section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the global AAT deficiency treatment market. The report also profiles major players in the market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Major companies competing in the non-vascular stents market, and profiled in the report include Grifols S.A., AstraZeneca, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, GlaxoSmithKline Plc., CSL Behring LLC, Shire plc, Pfizer Inc., LFB Biomedicaments S.A., Kamada Ltd.

The Global Alpha-1 Antitrypsin Deficiency Treatment Market has been segmented as follows:

Global Alpha-1 Antitrypsin Deficiency Treatment Market, by Treatment Type

  • Augmentation Therapy
    • Aralast
    • Prolastin
    • Zemaira/Respreeza
    • Glassia
  • Bronchodilator
  • Corticosteroids
  • Oxygen Therapy
  • Others

Global Alpha-1 Antitrypsin Deficiency Treatment Market, by Route of Administration

  • Parenteral
  • Inhalations
  • Oral

Global Alpha-1 Antitrypsin Deficiency Treatment Market, by End-User

  • Specialty Clinics
  • Hospitals
  • Pharmacies

Global Alpha-1 Antitrypsin Deficiency Treatment Market, by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa


 
 
Back To Top